B
Bjorn W H van Heumen
Researcher at Radboud University Nijmegen Medical Centre
Publications - 8
Citations - 355
Bjorn W H van Heumen is an academic researcher from Radboud University Nijmegen Medical Centre. The author has contributed to research in topics: Familial adenomatous polyposis & Duodenal cancer. The author has an hindex of 7, co-authored 8 publications receiving 316 citations.
Papers
More filters
Journal ArticleDOI
Over-expression of COX-2 mRNA in colorectal cancer
Hennie M.J. Roelofs,Rene H. M. te Morsche,Bjorn W H van Heumen,Fokko M. Nagengast,Wilbert H.M. Peters +4 more
TL;DR: Levels of COX-2 mRNA are found over-expressed in almost 80% of the colorectal tumors, compared to paired adjacent normal coloreCTal mucosa, suggesting a role of COx-2 as a potential biomarker for cancer risk, whereas inhibitors of COZ-2 could be of value in chemoprevention of colon cancer.
Journal ArticleDOI
Surgical management for advanced duodenal adenomatosis and duodenal cancer in Dutch patients with familial adenomatous polyposis: A nationwide retrospective cohort study
Bjorn W H van Heumen,Marry H. Nieuwenhuis,Harry van Goor,Lisbeth Mathus-vliegen,Evelien Dekker,Dirk J. Gouma,Jan Dees,Casper H.J. van Eijck,Hans F. A. Vasen,Fokko M. Nagengast +9 more
TL;DR: Prognosis of duodenal cancer in patients with FAP is poor, which justifies an aggressive approach to advanced benign adenomatosis, and strict adherence to recommended surveillance intervals is essential for a well-timed intervention.
Journal ArticleDOI
The Influence of Curcumin, Quercetin, and Eicosapentaenoic Acid on the Expression of Phase II Detoxification Enzymes in the Intestinal Cell Lines HT-29, Caco-2, HuTu 80, and LT97
Julia Odenthal,Bjorn W H van Heumen,Hennie M.J. Roelofs,Rene H. M. te Morsche,Brigitte Marian,Fokko M. Nagengast,Wilbert H.M. Peters +6 more
TL;DR: In this article, the effects of low-dose curcumin, quercetin, and eicosapentaenoic acid (EPA) on phase II detoxification enzymes UDP-glucuronosyltransferase (UGT), glutathione S-transferase, as well as on GSH content were analyzed in 4 cell line models of intestinal carcinogenesis.
Journal ArticleDOI
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial
Bjorn W H van Heumen,Hennie M.J. Roelofs,M. Elisa Vink-Börger,Evelien Dekker,Elisabeth M. H. Mathus-Vliegen,Jan Dees,Jan J. Koornstra,Alexandra M. J. Langers,Iris D. Nagtegaal,Ellen Kampman,Wilbert H.M. Peters,Fokko M. Nagengast +11 more
TL;DR: Celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, high dose UDCA co-treatment counteracts this effect, and the benefit of long term use of celecoxib for duodanal cancer prevention needs to be weighed against the (risk of) adverse events.
Journal ArticleDOI
Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells
Bjorn W H van Heumen,Hennie M.J. Roelofs,Rene H. M. te Morsche,Brigitte Marian,Fokko M. Nagengast,Wilbert H.M. Peters +5 more
TL;DR: Co-treatment with low dose celecoxib and UDCA has growth inhibitory effects on colorectal adenoma cells derived from a patient with FAP, and further research on this combination as promising chemopreventive strategy is desired.